HedgeChatter

  • Home /
  • Tag Archives

ARWR

Arrowhead Announces Pricing of Underwritten Offering of Common Stock

[Business Wire] – Arrowhead Research Corporation , a biopharmaceutical company developing targeted RNAi therapeutics, today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock, offered at a price of $18.95 per share. moreView todays social media effects on ARWRView the latest stocks trending across Twitter. Click to view dashboardSee who Arrowhead is hiring next, click […]

February 19, 2014 Bystocknews , Comments Off on Arrowhead Announces Pricing of Underwritten Offering of Common Stock read more

Arrowhead Announces Proposed Underwritten Offering of Common Stock

[Business Wire] – Arrowhead Research Corporation , a biopharmaceutical company developing targeted RNAi therapeutics, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf re moreView todays social media effects on ARWRView the latest stocks trending across Twitter. Click to view dashboardSee who Arrowhead is hiring next, click […]

February 18, 2014 Bystocknews , Comments Off on Arrowhead Announces Proposed Underwritten Offering of Common Stock read more

Arrowhead RNAi Candidate ARC-520 Induces Greater than 90% Reduction in Circulating HBV DNA in Chimpanzee with Chronic Hepatitis B

[at noodls] – About Arrowhead Research Corporation Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. … moreView todays social media effects on ARWRView the latest stocks trending across Twitter. Click to view dashboardSee who Arrowhead is hiring next, click here to view […]

March 14, 2013 Bystocknews , Comments Off on Arrowhead RNAi Candidate ARC-520 Induces Greater than 90% Reduction in Circulating HBV DNA in Chimpanzee with Chronic Hepatitis B read more

Arrowhead Receives Notice of Patent Allowance for New Protease Sensitive Masking Chemistry for DPC siRNA Delivery System

[at noodls] – About Arrowhead Research Corporation Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. … moreView todays social media effects on ARWRView the latest stocks trending across Twitter. Click to view dashboardSee who Arrowhead is hiring next, click here to view […]

February 28, 2013 Bystocknews , Comments Off on Arrowhead Receives Notice of Patent Allowance for New Protease Sensitive Masking Chemistry for DPC siRNA Delivery System read more

Arrowhead Reports Fiscal 2013 First Quarter Financial Results

[at noodls] – PASADENA, Calif. – February 13, 2013 – Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2013 first quarter ended December … moreView todays social media effects on ARWRView the latest stocks trending across Twitter. Click to view dashboardSee who Arrowhead is hiring next, click here to view […]

February 13, 2013 Bystocknews , Comments Off on Arrowhead Reports Fiscal 2013 First Quarter Financial Results read more

Arrowhead to Report Fiscal 2013 First Quarter Financial Results

[at noodls] – About Arrowhead Research Corporation Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. … moreView todays social media effects on ARWRView the latest stocks trending across Twitter. Click to view dashboardSee who Arrowhead is hiring next, click here to view […]

February 7, 2013 Bystocknews , Comments Off on Arrowhead to Report Fiscal 2013 First Quarter Financial Results read more